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Abstract Dehydroepiandrosterone sulfate (DHEAS) is the
major circulating steroid in man. Pharmacologically, it exerts
marked neuropsychiatric effects. Since no target receptor has
been identified, we investigated whether the organic anion
transporting polypeptide (OATP), a multispecific steroid carrier,
transports DHEAS. Expression of the human liver OATP in
Xenopus laevis oocytes resulted in high-affinity, partially Na+-
dependent uptake of [3H]DHEAS (Km : 6.6 Wmol/l). DHEAS
transport was inhibited by bromosulfophthalein, bile acids,
sulfated estrogens and dexamethasone. Northern blot analysis
showed widespread expression of OATP in human brain. These
data identify OATP as the first known target protein of DHEAS
in human liver and brain.
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1. Introduction
Dehydroepiandrosterone (DHEA) and its sulfated metabo-
lite DHEAS represent the major circulating steroids secreted
by the adrenal cortex in man. In human plasma DHEA con-
centrations average 10 nmol/l, while DHEAS concentrations
reach 10 Wmol/l in young adults 20^35 years of age [1]. Apart
from serving as precursors for endogenous testosterone and
estrogen synthesis [2], these hormones exert signi¢cant neuro-
psychiatric e¡ects. The vogue drug prasterone (DHEA) has
attained widespread popularity as an ‘anti-aging hormone’ in
the USA, since the age-related decrease in plasma concentra-
tions of DHEA(S) is held responsible for the decline of certain
physiological functions associated with aging. At age 80,
DHEA(S) levels are only about 20% those at age 25, unlike
the age-independent plasma levels of cortisol [3]. DHEA(S)
substitution induces an expressed feeling of remarkable psy-
chological and physical well-being, notably an improved qual-
ity of sleep, greater energy and an increased ability to handle
stress [4]. Oral administration of DHEA to elderly patients
with major depression signi¢cantly improves depression rat-
ings and memory performance [5].
After oral administration, DHEA is largely converted to
DHEAS in the liver and the plasma levels of the latter in-
crease rapidly [6]. The metabolism of DHEA into potentially
active sex steroids occurs in tissues possessing androgen or
estrogen receptors, notably in adipose tissue, muscle, prostate,
brain and particularly in the liver, from where active DHEA
metabolites are released into the circulation and reach their
target tissues [1]. DHEAS is strongly bound to albumin in
plasma and undergoes renal tubular reabsorption [6]. The
precise mode of action of DHEA(S) is unknown, since no
selective receptor has been identi¢ed. The aim of this study
was to identify a speci¢c transport protein which mediates
DHEAS transport in human liver and brain.
Of the known membrane proteins and receptors involved in
the uptake and metabolism of steroid hormones, the so-called
organic anion transporting polypeptide (OATP) ^ a trans-
membrane transport protein for anionic steroids with a strong
level of expression in the brain [7,8] ^ was considered a po-
tential candidate for speci¢c cell surface interaction with
DHEAS. Both the human OATP as well as its rat homo-
logues oatp-1 [9] and oatp-2 [10] have been shown to function
as multispeci¢c amphipathic steroid transporters for the con-
jugated steroids estrone-3-sulfate [8] and estradiol-17L-D-glu-
curonide [10,11]. To study whether the human OATP could
represent a physiological target protein for DHEAS in human
liver, kidney and brain, OATP-mediated DHEAS transport
was functionally characterized in the Xenopus laevis frog oo-
cyte expression system and OATP expression in human brain
determined by Northern blot analysis.
2. Materials and methods
2.1. Materials
7-3H(N)]Dehydroepiandrosterone sulfate ([3H]DHEAS) (21.1 Ci/
mmol) was obtained from DuPont-New England Nuclear, Bad Hom-
burg, Germany. [K-32P]Deoxycytidine triphosphate ([K-32P]dCTP)
(3000 Ci/mmol) was obtained from Amersham International, Buck-
inghamshire, UK. Dexamethasone, water soluble, was obtained from
Sigma, Deisenhofen, Germany.
2.2. Animals
Mature Xenopus laevis females were purchased from Nasco, Fort
Atkinson, WI, USA, and kept under standard conditions as described
[12].
2.3. Expression of human OATP in Xenopus laevis oocytes
The cDNA coding for the human OATP [7] was ligated direction-
ally into the plasmid pSPORT1 (Gibco BRL, Gaithersburg, MD,
USA). Plasmid DNA was prepared with the Qiagen miniprep system
(Qiagen, Hilden, Germany) and linearized with NotI. Capped comple-
mentary RNA was transcribed in vitro with T7 RNA polymerase
(Promega Corp., Madison, WI, USA) [13]. Xenopus laevis oocytes
were prepared as previously described [14]. After an overnight incu-
bation at 18‡C, healthy oocytes were microinjected with 10 ng of
human OATP complementary RNA and were subsequently cultured
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for 72 h in modi¢ed Barth’s solution [14] to allow expression of the
OATP.
2.4. DHEAS uptake in oocytes
Uptake of [3H]DHEAS was measured in an NaCl medium, consist-
ing of (in mmol/l) 100 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2 and 10 HEPES
adjusted to pH 7.5 with Tris. H2O-injected oocytes were used as
controls. Fifteen oocytes were prewashed in the uptake medium and
incubated at 25‡C in 100 Wl of the same medium containing
[3H]DHEAS at the indicated concentrations. Uptakes were stopped
by the addition of 3 ml ice-cold uptake bu¡er and oocytes were
washed with 3U10 ml of ice-cold uptake bu¡er. Each oocyte was
dissolved in 500 Wl of 10% SDS and 5 ml scintillation £uid (Ultima
Gold, Canberra Packard, Frankfurt/Main, Germany), and the oocyte-
associated radioactivity was counted in a Packard Tri-Carb 2100
liquid scintillation analyzer (Packard Instrument Co., Frankfurt/
Main, Germany).
2.5. Northern blot analysis
A Northern blot containing 2 Wg messenger RNA from eight di¡er-
ent human brain regions was purchased from Clontech Laboratories
Inc., Palo Alto, CA, USA. The blot was hybridized with a [K-
32P]dCTP-labeled human OATP-cDNA fragment as described previ-
ously [7] and was subsequently exposed to autoradiography ¢lm for
6 h.
2.6. Statistical analysis
Values are given as the mean þ 1 S.D. The level of signi¢cance of
DHEAS uptake in the cis-inhibition studies was determined using the
unpaired two-tailed Student’s t-test [15]. Statistical signi¢cance was
assumed at P6 0.05.
3. Results
3.1. Characterization of OATP-mediated [3H]DHEAS uptake
in oocytes
To establish whether DHEAS is a substrate of the organic
anion transporting polypeptide, oocytes injected with OATP-
cRNA or water were incubated with 10 Wmol/l [3H]DHEAS in
an NaCl medium. As shown in Fig. 1, there was clear stim-
ulation of DHEAS uptake in oocytes injected with OATP-
cRNA compared with water-injected control oocytes
(2.00 þ 0.47 pmol/oocyte vs. 0.26 þ 0.06 pmol/oocyte, respec-
tively, after 30 min). In a Na-free medium, in which NaCl
had been replaced by 100 mmol/l choline chloride, DHEAS
uptake amounted to 0.60 þ 0.02 vs. 0.19 þ 0.02 pmol/oocyte/30
min in OATP-expressing and water-injected oocytes respec-
tively, indicating partial Na-dependence of DHEAS uptake.
To analyze the kinetics of OATP-mediated DHEAS transport,
oocytes were incubated with [3H]DHEAS at increasing sub-
strate concentrations over a period of 30 min. As shown in
Fig. 2, DHEAS uptake was saturable and of high a⁄nity,
with an apparent Km of 6.6 þ 1.3 Wmol/l and a Vmax of
2.6 þ 0.1 pmol/oocyte/30 min. This Km value is in the range
of DHEAS concentrations in human plasma and central nerv-
ous system [16], indicating that OATP could be the physio-
logical transport system for this steroid.
To further characterize OATP-mediated DHEAS transport,
the cis-inhibitory e¡ect of a variety of conjugated steroids and
OATP substrates on DHEAS uptake was examined. OATP-
expressing and water-injected Xenopus laevis oocytes were in-
cubated with 5 Wmol/l [3H]DHEAS in the presence of 100
Wmol/l of the respective inhibitor substances. As shown in
Fig. 3, OATP-mediated DHEAS uptake was signi¢cantly in-
hibited by the cholephilic organic anion bromosulfophthalein
(BSP) (67.5 þ 16.4% inhibition) and by the bile acids tauroche-
nodeoxycholate (75.2 þ 23.9%) and tauroursodeoxycholate
(85.7 þ 24.1%). Strong inhibition was also observed in the
presence of the OATP substrate estrone-3-sulfate
(82.3 þ 17.2%), its 17-hydroxylated derivative estradiol-3-sul-
fate (92.9 þ 22.0%) and the glucocorticoid dexamethasone
(97.3 þ 10.1%).
3.2. Northern blot analysis of OATP expression in human brain
Since OATP had previously been found to be strongly
abundant in human brain [7], its distribution in eight di¡erent
brain regions was investigated by Northern blot analysis. Fig.
4 shows the characteristic pattern of multiple OATP tran-
scripts in all human brain regions tested, with a major hybrid-
ization signal at 7.8 kbp and additional cross-hybridizing mes-
senger RNAs of approximately 2.7 kbp, 3.3 kbp and 4.4 kbp.
The original size of the cloned human liver OATP cDNA
corresponds to the 2.7 kbp band. These data indicate abun-
dant expression and widespread distribution of OATP in the
human brain, explaining the marked neuropsychiatric e¡ects
of DHEA(S) on the central nervous system.
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Fig. 1. Transport of DHEAS by the human OATP. Xenopus laevis
oocytes were injected with 10 ng OATP-cRNA (b) or with an iden-
tical volume of H2O (a). After 3 days in culture, uptake of (10
Wmol/l) [3H]DHEAS was measured in an NaCl medium. Data repre-
sent the mean þ 1 S.D. of 15 independent oocyte uptake measure-
ments.
Fig. 2. Kinetics of DHEAS uptake in OATP-cRNA-injected oo-
cytes. Oocytes were injected with 10 ng OATP-cRNA or with an
identical volume of H2O. After 3 days in culture, uptake of
[3H]DHEAS was measured in an NaCl medium in the presence of
increasing substrate concentrations. Uptake was measured over 30
min, since separate experiments showed linear uptake during this
time period at low (0.5 Wmol/l) and high (100 Wmol/l) substrate con-
centrations. Non-speci¢c di¡usion into H2O-injected oocytes was
subtracted from all uptake values. Individual data points represent
the mean þ 1 S.D. of 12^15 oocyte uptake measurements. The curve
was ¢tted by non-linear regression analysis.
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4. Discussion
The present study identi¢es the organic anion transporting
polypeptide, a multispeci¢c amphipathic steroid transporter,
as the ¢rst known target protein of the sex hormone precursor
and established psychotropic steroid DHEAS. In the Xenopus
laevis oocyte expression system, injection of OATP-cRNA
signi¢cantly stimulated uptake of DHEAS compared to
water-injected control oocytes (Fig. 1). Kinetic analysis re-
vealed a high a⁄nity of OATP-mediated DHEAS transport,
with an apparent Km of 6.6 Wmol/l and a Vmax of 2.6 pmol/
oocyte/30 min (Fig. 2). This Km value is in the range of
DHEAS concentrations in plasma and brain [16], indicating
that OATP could be the physiological DHEAS transport sys-
tem. OATP-mediated DHEAS uptake was inhibited by the
OATP substrates BSP, taurochenodeoxycholate, taurourso-
deoxycholate, sulfated estrone and estradiol, as well as by
the structurally related glucocorticoid dexamethasone (Fig.
3). Finally Northern blot analysis of OATP expression in
the brain showed that multiple transcripts are present in all
brain regions tested. This could explain the pronounced neu-
ropsychiatric e¡ects exerted by DHEAS.
The rationale for studying DHEAS transport via OATP
originated from the observation that several tissues involved
in DHEAS uptake and metabolism also express the steroid
transporter OATP. DHEAS is largely formed from DHEA in
the liver [6], from where it is e¥uxed across the sinusoidal
hepatocyte membrane back into the circulation. OATP is a
bidirectional transport system [17], which functions as an
anion exchanger to facilitate the transport of organic anions
such as conjugated steroids across the basolateral hepatocyte
membrane. Similar anion exchange mechanisms exist in prox-
imal tubular kidney cells, which also express OATP on their
apical surface [18]. Apart from mediating tubular reabsorp-
tion of conjugated steroids such as DHEAS, OATP serves as
an apical secretory pathway for numerous other steroids fol-
lowing their conjugation by sulfotransferases within the tubule
cell. In the rat brain, the OATP homologue oatp-1 has been
localized to the apical surface of choroid plexus epithelial cells
[19], which is in contact with the cerebrospinal £uid. Since the
choroid plexus epithelium is known to share many functional
properties with hepatocytes, such as active transport of organ-
ic anions [19], oatp-1 is likely to be the mediator of vectorial
organic anion transport between choroid plexus and cerebro-
spinal £uid.
The Northern blot data presented in this study indicate that
in the human brain, a major site of DHEAS action and me-
tabolism, there is widespread distribution and abundant ex-
pression of OATP. Although DHEAS hardly crosses the
blood-brain barrier [20], de novo synthesis of neurosteroids
by oligodendroglial cells leads to cerebral accumulation of
DHEAS [16,21]. The function of OATP in the brain could
be to mediate the release of DHEAS into the extracellular
space following its synthesis in glial cells. DHEAS action in
the central nervous system appears to occur via binding to
synaptosomal membranes [16]. DHEAS is a negative non-
competitive modulator of the GABAA receptor [16] and an
agonist of the c1 receptor, modulating N-methyl-D-aspartate-
mediated glutamatergic neurotransmission [22]. Because
DHEAS concentrations in the brain are subject to physiolog-
ical variations, this neurosteroid could play an important role
in regulating neuronal excitability in the central nervous sys-
tem.
An active basolateral transport system for DHEAS has
been characterized in rat hepatocytes [23]. Interestingly,
DHEAS uptake into rat hepatocytes was saturable, partially
Na-dependent and inhibited by bile acids. Conversely, the
uptake of [3H]cholate was strongly inhibited by DHEAS.
These results indicated that DHEAS is a substrate of the
multispeci¢c hepatocellular bile acid uptake system [23]. Since
OATP is the only known multispeci¢c hepatocellular bile acid
transporter [24] and possesses all the functional characteristics
of the DHEAS uptake system described in rat hepatocytes, it
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Fig. 4. Northern blot analysis of OATP expression in human brain.
The Northern blot contained 2 Wg of poly(A) RNA from each hu-
man brain region. After hybridization with a 32P-labeled OATP-
cDNA fragment (see Section 2), the blot was exposed to autora-
diography ¢lm for 6 h.
Fig. 3. E¡ects of organic anions and steroids on DHEAS uptake in
OATP-cRNA-injected oocytes. Oocytes were injected with 10 ng
OATP-cRNA or with an identical volume of H2O. After 3 days in
culture, uptake of 5 Wmol/l [3H]DHEAS was measured in an NaCl
medium in the absence (controls) or presence of 100 Wmol/l of the
indicated inhibitor substances. Non-speci¢c di¡usion into H2O-in-
jected oocytes was subtracted from all uptake values. BSP, bromo-
sulphophthalein; TCDC, taurochenodeoxycholate; TUDC, taurour-
sodeoxycholate. Individual data points represent the mean þ 1 S.D.
of 12^15 oocyte uptake measurements. All uptake values in the
presence of inhibitor substances were signi¢cantly di¡erent
(P6 0.001) from controls.
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probably represents the major DHEAS transport system of
human liver.
In summary, OATP mediates high-a⁄nity transmembrane
transport of DHEAS and thus represents the ¢rst known tar-
get protein of this major circulating steroid in man. The hep-
atocellular and renal tubular transport as well as the numer-
ous psychotropic e¡ects of the neuroactive steroid DHEAS
could be attributable to the expression of OATP in these
tissues.
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